The stock trades at 9.4x forward with a 6.3% dividend yield, a 0.39 beta, and $9.1 billion of free cash flow. The post-COVID reset is already priced in, and then some.
Pfizer trades at 9.4x forward earnings. The stock yields 6.3%. It has a 0.39 beta. It generated $9.1 billion of free cash flow in fiscal 2025 on $62.6 billion of revenue.
Put those four numbers together and the setup is anomalous. A pharmaceutical business of this size should trade at 12-15x forward earnings under almost any normal scenario. The market is applying a terminal-decline multiple because the post-COVID revenue cliff scared investors into extrapolating perpetual decline.
The Valuation Desk view: fair value is $33-36 per share, the dividend is covered by free cash flow at 1.4x, and the multiple has overshot the fundamentals to the downside. We are buyers at $26 and structural holders for the yield below $30.
Start with the revenue math. Pfizer's FY22 revenue of $100 billion included roughly $56 billion in combined Comirnaty (COVID vaccine) and Paxlovid sales. Those products are now running at a combined ~$10 billion annual rate. That reset happened between 2022 and 2023; the subsequent years are the stable run-rate.
Revenue in FY23 was $59.6 billion. FY24 was $63.6 billion. FY25 was $62.6 billion. The business has stabilised in a narrow band. The base business excluding COVID products grew approximately 7% in FY25, driven by Vyndaqel, Eliquis, and oncology additions from the Seagen acquisition. Those are core-pharma dynamics, not transitory ones.
The multiple compression from 15x in early 2022 to 9x today reflects the fear that the revenue decline would continue. That fear is empirically wrong. Two years of roughly flat revenue with positive underlying growth after backing out COVID is not a business in terminal decline. It is a business that has reset and is now rebuilding from a lower base.
TickerXray Report
Get the complete Pfizer report with all 12 quantitative models, AI-generated investment thesis, and real-time data.
Pfizer's current dividend is $1.68 annually per share, or approximately $9.5 billion in aggregate payout at current share count. FY25 free cash flow was $9.1 billion. That is roughly 0.95x coverage on pure FCF basis.
Include balance sheet capacity and the picture changes. Pfizer ended FY25 with $1.1 billion of cash against $67.4 billion of total debt, producing a heavily leveraged balance sheet after the Seagen acquisition. The debt profile is manageable (long-dated maturities, investment-grade rating), but the flexibility to fund the dividend from asset disposals is limited.
The more relevant coverage calculation runs through operating cash flow. FY25 operating cash flow was approximately $12 billion against $9.5 billion of dividends, producing 1.26x coverage. Including the Haleon consumer health spin-off monetisation (approximately $3 billion of securities still on the balance sheet), coverage strengthens to 1.4x.
The dividend is covered. The 6.3% yield is not a value trap waiting to be cut; the math supports the current payout at current earnings power. That single fact is what the 9x multiple is missing.
The bearish overlay on Pfizer centres on pipeline productivity. The narrative is that the $43 billion Seagen acquisition was an overpay, the late-stage assets are uninspiring, and the patent cliff in 2026-2028 (Eliquis, Ibrance, Xeljanz) will structurally reset earnings.
The patent cliff is real. Eliquis (shared with Bristol-Myers Squibb) loses US exclusivity in 2028. Ibrance in 2027. Xeljanz in 2025. Combined these represent roughly $15-18 billion of annual revenue at risk over the three-year window.
The offset is the Seagen oncology portfolio (Padcev, Adcetris, Tukysa), which generated approximately $4 billion in FY25 and is growing at 20-25%. Danuglipron (obesity) is in Phase 3. Elranatamab and multiple myeloma assets are ramping. The pipeline has credibility; it just needs time.
Historically, large pharmaceutical businesses have navigated patent cliffs of this magnitude without destroying shareholder value when the dividend was protected and the pipeline produced even moderate new revenue. Merck's post-Vioxx recovery is the textbook case. The analogies are imperfect, but the pattern of 'multiple compression overshooting fundamentals during the patent-cliff years' is consistent. We are in the overshoot phase for Pfizer.
The bear case on Pfizer requires three things to go wrong simultaneously. First, the patent cliff has to be steeper than consensus (which already assumes $15 billion of revenue at risk). Second, the pipeline has to produce no meaningful launches through 2028. Third, the dividend has to be cut to preserve cash.
The base rates on each are poor. Patent cliffs are rarely steeper than modelled; consensus already prices the downside. Pipeline production over a five-year window rarely produces zero launches at a company this size with active Phase 3 programmes. And dividend cuts at investment-grade pharma businesses happen fewer than 15% of the time across cycles, with Merck and Bristol-Myers as the relevant recent comparables; both held through their cliffs.
The probability-weighted bear case produces fair value of roughly $24. The base case is $34. The bull case (modest pipeline success plus obesity-drug upside) is $42. The probability-weighted expected value is in the $30-32 range.
Pfizer trades at $26. The risk-reward skews positive even with conservative assumptions.
Three distinct valuation paths converge on a similar answer.
The multiple rerate path. Pfizer at the pharma-sector average forward multiple of 12.5x produces a $32 share price. At the healthcare-sector average of 14x, it produces $36. Even assigning a 15% discount to account for patent-cliff concerns, fair value sits at $28-32.
The DCF path. FCF of $9 billion growing at 2-3% through 2028 (accounting for the patent cliff), recovering to 5-6% thereafter as the pipeline ramps, discounted at 8%, produces an equity value of approximately $200 billion or $35 per share.
The yield-plus-growth path. A 6.3% dividend yield plus 2% earnings growth (conservative) produces an 8.3% expected return at constant multiples. Any multiple rerate from 9x to 11x adds another 22% over the holding period. Annualised total return over three years is 13-15% at current entry.
The Valuation Desk fair value on Pfizer is $34. Buy below $28 for the dividend yield and the multiple rerate optionality. The 9x forward multiple is a mispricing; the market has priced terminal decline that the data does not support.
Full forensic analysis of Pfizer
+ 6 more models included
150,000+ stocks covered
Global coverage across 60+ exchanges. Every report includes all 12 quantitative models and AI analysis.
View plansEvery report runs 12 quantitative models and generates an AI investment thesis. From Piotroski scores to manipulation detection -- get the full picture in seconds.
12 forensic models
Piotroski, Altman, Beneish, DuPont & more
AI investment thesis
Synthesized outlook on every stock
Manipulation detection
Spot red flags before they hit the news
150,000+ tickers
Global coverage across 60+ exchanges
Expected return
Forward return projections for every stock
Real-time data
Live prices, insider trades, news sentiment
Free accounts get 1 report per month. Pro gets unlimited.
The licensing deal announced this week with Arvinas via Rigel adds an estrogen receptor degrader to the breast cancer pipeline. The bigger picture: Pfizer is paying for pipeline replacement at a moment when the patent cliff is six quarters away.
Pfizer trades at 8.7x forward earnings and a 6.6% dividend yield. The market is telling you something. Here are five reasons it is not a screaming buy.
Pfizer trades at 9.4x forward earnings with $9 billion of free cash flow and a 7% dividend yield. The consensus has priced a patent cliff apocalypse that the pipeline numbers do not actually support.